NCT02120950 - Aflibercept in Polypoidal Choroidal Vasculopathy | Biotech Hunter

Enrollment

333

Participants

Timeline

Start Date

May 29, 2014

Primary Completion Date

August 12, 2016

Study Completion Date

July 7, 2017

Conditions

Neovascular Macular Degeneration

Interventions

DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Eylea is administered as an intravitreal injection

OTHER

Visudyne

Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)

Trial Locations (62)

500

Changhua

1082

Budapest

1106

Budapest

1133

Budapest

2135

Strathfield

2145

Westmead

2150

Parramatta

2170

Liverpool

3002

East Melbourne

4032

Debrecen

10002

Taipei

10449

Taipei

11217

Taipei

80336

München

81362

Kaohsiung City

119074

Singapore

168751

Singapore

Unknown

Hong Kong

Kowloon

Taipei

466-8560

Nagoya

279-0021

Urayasu

503-0015

Ōgaki

371-8511

Maebashi

078-8510

Asahikawa

060-8604

Sapporo

660-8550

Amagasaki

650-0017

Kobe

761-0793

Kita

514-8507

Tsu

634-8522

Kashihara

573-1191

Hirakata

565-0871

Suita

520-2192

Ōtsu

430-8558

Hamamatsu

329-0498

Shimotsuke

113-8655

Bunkyo-ku

101-8309

Chiyoda-ku

152-8902

Meguro-ku

181-8611

Mitaka

160-8582

Shinjuku-ku

162-8666

Shinjuku-ku

010-8543

Akita

030-8553

Aomori

260-8677

Chiba

812-0011

Fukuoka

812-8582

Fukuoka

960-1295

Fukushima

860-0027

Kumamoto

602-0841

Kyoto

606-8507

Kyoto

852-8511

Nagasaki

700-8558

Okayama

545-8586

Osaka

770-8503

Tokushima

641-8510

Wakayama

463-707

Seongnam-si

03080

Seoul

05505

Seoul

135-710

Seoul

137-701

Seoul

153-950

Seoul